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Background: There is limited information on the causes of death in asthma patients.
To determine the causes of death in hospitalized asthmatic patients and to compare with those observed in COPD
patients and non-respiratory individuals, with a particular interest in associations with previous cardiovascular disease.
Methods: Retrospective case–control study which analyzed the deaths of all hospitalized patients admitted for any
reason during January, April, July and October of 2008 in 13 Spanish centers. Medical records of deceased patients
were reviewed, and demographic and clinical data were collected.
Results: A total of 2,826 deaths (mean age 75 years, 56% men) were included in the analysis, of which 82 (2.9%) were
of patients with asthma and 283 (10%) with COPD.
The most common causes of death in asthma patients were cardiovascular diseases (29.3%), malignancies (20.7%) and
infections (14.6%); in COPD patients they were malignancies (26.5%), acute respiratory failure (25.8%) and cardiovascular
diseases (21.6%). Asthma, compared to COPD patients, died significantly less frequently from acute respiratory failure
and lung cancer. A multivariate logistic regression analysis failed to associate asthma with cardiovascular deaths.
Conclusions: Cardiovascular disease is the most frequent cause of death among hospitalized asthma patients. The
specific causes of death differ between asthma and COPD patients.
Keywords: Asthma, COPD, Respiratory failure, Mortality, Cardiovascular diseases.Background
After the epidemics of asthma deaths during the
1990s, numerous International [1,2] and national [3-5] re-
cent studies have confirmed a consistent decrease in mor-
tality. Among the causes of this decline, the correct
implementation of clinical practice guidelines has been
postulated [6-8], and particularly, the increasingly uni-
versal use of inhaled corticosteroids as maintenance
asthma treatment [9,10].
Unlike COPD, for which mortality has risen during
the same period [11], the reduced mortality from asthma* Correspondence: josesoto@separ.es
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distribution, and reproduction in any mediumhas perhaps contributed to a reduced knowledge on the
clinical characteristics and circumstances of death in
asthmatics. Thus, contrary to COPD patients, in whom
numerous recent studies have characterized their causes
of death, in asthma patients there has been considerably
less research. It is well established that in COPD, serious
exacerbations, respiratory failure, cardiovascular diseases,
and bronchopulmonary malignancies constitute the prin-
cipal causes of death [12-14]. Variation in the relative im-
portance of these causes according to the severity of
COPD has also been described as lung cancer is the prin-
cipal cause of death in mild COPD, while respiratory fail-
ure is in very severe COPD [15].
In asthma, the possible causes of death are still not well
understood, except for the recognized reduced contribu-
tion of severe asthma exacerbations. The few studiesentral Ltd. This is an open access article distributed under the terms of the
/creativecommons.org/licenses/by/2.0), which permits unrestricted use,
, provided the original work is properly cited.
Soto-Campos et al. BMC Pulmonary Medicine 2013, 13:73 Page 2 of 8
http://www.biomedcentral.com/1471-2466/13/73available are limited to those designed with other epi-
demiological objectives [16]; others have been conducted
in specific population groups (women [17], children [18]),
or are based on series of deaths too small to draw strong
conclusions [19].
Furthermore, the bronchial and systemic inflammation
and the clinical impact of the associated comorbidities
in asthma [20-23] have provided evidence for suspecting
that, as in COPD [12,24], asthma patients might be at a
greater risk of suffering cardiovascular [25,26] and cere-
brovascular [27] diseases and, therefore at risk of death
due to vascular events [17,19]. However, previous studies
exploring this association have reported conflicting re-
sults, and few of these have managed to determine a
causal relationship between asthma and cardiovascular
disease. Also, the method used in some of these studies
could be questioned. For example, the diagnosis of
asthma was assumed from simple self-reporting by pa-
tients [19,25-27]; and, in others, by their responses col-
lected in a telephonic survey addressed to recognize
asthma symptoms [17].
Our study was designed with two objectives: to deter-
mine the causes of death of patients with asthma com-
pared with those of patients with COPD; and to establish
a possible relationship between deaths from asthma and
cardiovascular diseases. In Spain about 68% of deaths
occur in hospitals with certain regional geographic vari-
ation [28]. We believe that the information collected is
representative because most of the Spanish population
deaths occur in hospitals.
Methods
Observational, retrospective, cross-sectional, multi-centre
study conducted in a large group of patients who died
while admitted in hospital.
Fieldwork included all deaths in admitted patients dur-
ing the months of January, April, July and October
(months taken as representative of each of the four
seasons) of 2008 in thirteen Spanish secondary and ter-
tiary hospitals. The clinical records of all deceased pa-
tients were reviewed, and the following data were
collected: demographic data; existence of risk factors
for cardiovascular diseases (smoking, diabetes, arterial
hypertension, obesity, hyperlipidaemia); and specific
causes of death, distinguishing specifically lung cancer
within neoplastic disorders, the pneumonia within in-
fections; and within cardiovascular disease, peripheral
arteriopathy, ischemic cardiopathy, cerebrovascular dis-
ease or heart failure. In addition, in patients with asthma,
severity and control (both by GINA [6] and GEMA [8]
criteria); the frequency of scheduled and unscheduled
medical visits, spirometry (best FEV1 recorded) and
prescribed treatment were also recorded for each
death. The study protocol was approved by a centralethics committee (Hospital of Jerez) following the rules
of the Helsinki Declaration.
Previous asthma diagnosis was considered of a high
degree of certainty, when the clinical record contained
diagnostic confirmatory reports (signed by a pulmonolo-
gist or allergy specialist) with objective tests like either
significant variability of the spirometric flows performed
by applying a bronchodilatator or bronchoconstriction
challenge test; alternatively, a label of moderate degree
of certainty was given in absence of the above men-
tioned criteria and any of the following: the patient clin-
ical record reported symptoms compatible with asthma,
prescription of asthma drugs or an indication that the
attending physician during the hospital admission pre-
sumed the asthma diagnosis. Indistinguishable cases
from COPD, bronchiectasis or residual pulmonary le-
sions after tuberculosis co-existed, were excluded from
the analysis. A diagnosis of COPD was considered
when there was a diagnostic medical report (signed by
a pulmonologist) supported by poorly reversible air-
flow limitation with a post-bronchodilator FEV1/FVC
ratio < 0.70 ( GOLD criteria) [29].
Statistical analysis
A descriptive analysis was carried out for all variables
collected. Summary results were expressed as percent-
ages, frequencies and number of observations for quali-
tative variables, and as means with standard deviation
for quantitative variables.
We check the normality or otherwise of the sample
using the Kolmogorov Smirnov. Comparisons between
groups were performed using the χ 2 test for categorical
variables; and for quantitative variables, the ANOVA
test, or the Kruskall-Wallis test if values did not have a
normal assumption. For control of type I error rate, we
penalized or adjusted p values for multiple comparisons.
A multivariate logistic regression analysis was performed
to determine the possible independent association of a
previous diagnosis of asthma with death due to cardio-
vascular disease; this latter was considered both globally
and stratified by four predetermined categories (periph-
eral arterial disease, ischemic cardiopathy, cerebrovascu-
lar disease, and heart failure). The dependent variable
was death by cardiovascular diseases and the independ-
ent variables, a previous diagnosis of asthma or COPD,
age, sex, smoking, previous history of diabetes mellitus,
obesity, hyperlipidaemia, and arterial hypertension. Com-
parisons with a p value <0.05 were considered statistically
significant.
Results
The cause of death was determined according to certifi-
cation that existed in medical history signed by the doc-
tor who treated the patient, no death was excluded. A
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these, 1,583 (56%) were men. The mean ± SD age was 75 ±
14 years (74 ± 14 in men vs 77 ± 15 in women, p = 0.01).
The most frequent causes of death observed in the total
sample were: 746 (27%) malignancies, of which 173 (23%)
were lung cancer; 710 (25.7%) cardiovascular diseases (258
heart failure, 208 cerebrovascular disease, 191 ischemic
cardiopathy, and 53 peripheral arterial disease); and 597 in-
fections (21%), of which 332 (54.6%) pneumonia. Farther
251 deaths were observed gastrointestinal origin (9%) and
206 from respiratory failure (72 COPD patients, 5 asth-
matics and 131 from other causes and unclear diagnoses).Table 1 Demographic and clinical characteristic in the 2,826 d
of the two diseases (without asthma/COPD)
Asthma (n = 82) COPD (n
Age (years), mean (SD) 75 (15) 76 (9
CI 95% (60–80) (68–8
Sex n(%)
– Men 18 (22) 256 (90
– Women 64 (78) 27 ( 9
Smoking n (%)
– Smoker 8 (10.5) 64 (22
– Former smoker 9 (11.8) 208 (73
– Non smoker 58 (77.7) 10 (3.
Diabetes n (%)
28 (34.6) 77 (27
Hyperlipidaemia n (%)
26 (32.1) 58 (21
AHT n (%)
43 (52.8) 184 (65
Obesity BMI > 30 kg/m2 n (%)
27 (32.8) 57 (20
BMI, mean (SD) CI 95%
27.6 (7) 25.2 (5
(20,6-34,6) (19,8-3
Footnote:
Values represent means (standard deviation) or number of cases (percentage).
AHT, arterial hypertension; BMI, body mass index.
*comparisons between asthma group and COPD group
†comparisons between asthma group and group with neither asthma nor COPD.
¶comparisons between COPD group and group with neither asthma nor COPD.
comparisons between groups using the χ2 test for the categoric variables; and for the
if the values did not present a normal distribution.
We considered significanta p-value < 0.005.Table 1 presents and compares the demographic and
clinical characteristics of the sample distributed in,
COPD (283 [10%]), asthma (82 [2.9%]) and neither of
these two diseases (2,461 [87%]) groups. Patients with
COPD were more frequently male and smokers, while
those with asthma were more frequently obese (p < 0.001).
The overall comparison of the three groups using ANOVA
showed significant differences in gender (p < 0.001), smok-
ing (p < 0.001), obesity (p = 0.002) and BMI (p < 0.001).
The most frequent causes of death in asthmatics
(Table 2) were cardiovascular diseases (29.3%), malignan-
cies (20.7%) and infections (14.6%); in COPD patients,eaths analyzed, by diagnosed asthma, COPD or neither
= 283) Without asthma/COPD (n = 2.461) Value of p
0.350*
) 75 (14) 0.690†
5) (61–89) 0.310¶
.4) 1280 (53.0) < 0.001*
.6) 1171 (47.0) < 0.001†
< 0.001¶
.7) 295 (13.8) < 0.001*
.6) 547 (25.5) 0.008†
7) 1300 (60.7) < 0.001¶
0.266*
.7) 652 (26.9) 0.081†
0.417¶
0.035*
.5) 590 (24.8) 0.090†
0.121¶
0.148*
.0) 1321 (53.7) 0.529†
0.030¶
0.033*
.1) 339 (13.8) < 0.001†
0.011¶
0.061*
.4) 23.7 (6) < 0.001†
0,6) (17,7-29,7) 0.002¶
ordinal or quantitative variables, using the ANOVA test, or the Kruskall-Wallis test
Table 2 Causes of death in the 2,826 deaths analyzed, by diagnosed asthma, COPD or neither of the two diseases
(without asthma/COPD)
Causes of death Asthma (n = 82) COPD (n = 283) Without asthma/COPD (n = 2.461) Value of p
Solid malignancies, n (%) 17 (20.7) 75 (26.6) 654 (26.6) < 0.001*
– Pulmonary, n (%) 1 (1.2) 41 (14.5) 131 (5.3) 0.088†
< 0.001¶
Cardiovascular diseases, n (%) 24 (29.3) 61 (21.6) 641 (26.1)
– Ischemic cardiopathy, n (%) 6 (7.3) 16 (5.6) 169 (7.0) 0.100*
– Cerebrovascular accident, n (%) 6 (7.3) 19 (6.7) 183 (7.6) 0.394†
– Peripheral arteriopathy, n(%) 0 (0.0) 9 (3.2) 44 (1.8) 0.136¶
– Heart failure, n (%) 12 (14.6) 17 (6.0) 229 (9.5)
Infections, n (%) 12 (14.6) 46 (16.3) 539 (21.9) 0.154*
– Pneumonias n (%) 5 (6.0) 29 (10.3) 298 (12.1) 0.192†
0.320¶
Digestive diseases, n (%) < 0.001*
7 (8.5) 19 (6.7) 225 (9.2) < 0.001†
< 0.001¶
Respiratory insufficiency, n (%) < 0.001*
5.0 (6) 72 (25.5) 122 (4.9) < 0.001†
< 0.001¶
Other♯, n (%) < 0.001*
17 (20.9) 9 (3.3) 275 (11.3) < 0.001†
< 0.001¶
Footnote:
Values represent means (standard deviation) or number of cases (percentage).
Includes deaths from diseases of the blood and hematopoietic organs, diseases of the Central Nervous System, endocrine diseases, pulmonary thrombo-embolism,
diseases of the connective tissue, renal insufficiency, and accidents.
*comparisons between asthma group and COPD group.
†comparisons between asthma group and group with neither asthma nor COPD.
¶comparisons between COPD group and group with neither asthma nor COPD.
Comparisons between groups using the χ2 test for the categoric variables; and for the ordinal or quantitative variables, using the ANOVA test, or the Kruskall-Wallis test
if the values did not present a normal distribution.
We considered significanta p-value < 0.005.
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was broncho-pulmonary), acute respiratory failure (25.5%)
and cardiovascular diseases (21.6%). It is worth noting that
the proportion of patients who died from pneumonia in
the COPD group (59% of all fatal infections), was greater
than in the asthma group (39%), but this difference did
not reach statistical significance (p = 0.15). Only five (6%)
deaths due to respiratory failure (exacerbation) were docu-
mented in the asthma group, while 72 (25.5%) occurred in
patients with COPD (p < 0.05). The comparison of the
causes of mortality among the three groups using
ANOVA showed significant differences in solid malig-
nancies (p < 0.001), respiratory insufficiency (p < 0.001)
and other causes (p = 0.008).
The clinical and functional respiratory characteristics
of cases with asthma are shown in Table 3 (differences
between asthma high certainty and asthma lower certainty).
Notable among these results are the small proportion ofpatients with asthma well controlled (14.5%), the high fre-
quency of moderate or severe persistent asthma (49%), and
the high frequency of patients with a history of hospital ad-
mission for an asthma exacerbation (48%). As well the low
rates of preventative treatment received by patients: 16.9%
without treatment; 14.1% only with a short acting β2-
adrenergic agonist on rescue medication; and 2.8%
with a long-acting β2-adrenergic agonist without in-
haled corticosteroids.
The results of the multivariate analysis to determine
the risk factors associated with death by cardiovascular
diseases, are shown in Table 4. It is reported an associ-
ation with the well-known classical cardiovascular risk
factors, namely diabetes, age, hyperlipidaemia, but there
was no association with a previous asthma diagnosis.
When ‘death due to cardiovascular disease’ was stratified
into the four categories considered independently (cerebro-
vascular disease, ischemic cardiopathy, peripheral arterial
Table 3 Previous clinical and functional respiratory characteristics of all patients with asthma who died, by the degree
of certainty of the diagnosis of asthma
All (n = 82) Asthma high certainty* (n = 26) Asthma lower certainty* (n = 56) Value of p
Age mean (SD) 75 (15) 70 (15) 78 (15) 0.061
Sex
– men 52 23.1 21.4 0.869
– women 47 76.9 78.6
BMI mean (SD) 23.7 (6) 27.8 (7.2) 27.5 (7.1) 0.900
Hospitalizations due to asthma. n (%)
– Patients admitted 26 (48.1) 10 (38.5%) 16 (28.6%) 0.838
– Number of admissions per patient 2.03 (1.8) 2.83 (2.3) 1.55 (1.3)
Asthma control (GINA), n (%)
Uncontrolled 41 (59.4) 14 (58.3) 27 (60) 0.791
Partly controlled 18 (26.1) 6 (25.0) 12 (26.7)
Controlled 10 (14.5) 4 (16.7) 6 (13.3)
GINA severity, n (%)
Intermittent, 17 (28.8) 3 (14.3) 14 (36.8) 0.075
Persistent, mild 13 (22.0) 2 (9.5) 11 (28.9)
Persistent, moderate 21 (35.4) 11 (52.4) 10 (26.4)
Persistent, severe 8 (13.6) 5 (23.8) 3 (7.9)
Spirometry, mean (SD)
– FEV1, ml 1.215 (767) 1453 (739) 907 (709) 0.692
– FEV1,% 64.4 (23) 63.2(22.4) 66.5 (25.2)
Previous maintenance treatment, n (%)
– LABA + ICS 19 (26.7) 12 (46.1) 7 (15.6) 0.122
– LABA + ICS + LTRAs 13 (18.3) 8 (30.8) 5 (11.1)
– No treatment 12 (16.9) 3 (11.5) 9 (20)
– Short-acting β2-adrenergic agonist 10 (14.1) 2 (7.8) 8 (17.8)
– LTRAs 9 (12.7) 0 9 (20)
– LABA+ICS+oral corticosteroids 3 (4.2) 0 3 (6.7)
– Other:
– Ipratropium bromide 2 (2.8) 0 2 (4.4)
– LABA only 2 (2.8) 1 (3.8) 1 (2.2)
– ICS only 1 (1.4) 0 1 (2.2)
Footnote: Values represent means (standard deviation) or number of cases (percentage).
FEV1, forced expiratory volume in the first second; ICS, inhaled corticosteroids; LABA, long-acting β2-adrenergic agonists; LTRAs, leukotriene receptor antagonists.
*Comparisons between groups were not significant using the χ2 test for the categoric variables; and for the ordinal or quantitative variables, using the ANOVA
test, or the Kruskall-Wallis test if the values did not present a normal distribution.
Differences between asthma high certainty and asthma lower certainty.
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previous asthma diagnosis as well; OR 0.85 (95% CI 0.36 to
2.01) p = 0.74 for cerebrovascular disease; 0.86 (95% CI
0.33 to 2.21) p = 0.76 for ischemic cardiopathy; undeter-
mined by peripheral arterial disease and OR 1.57 (95% CI
0.83 to 2.99) p = 0.16 for heart failure (see Table 5).
The main results were not substantially modified when
asthmatics were divided according to the degree of cer-
tainty of the asthma diagnosis.Discussion
The main finding of the present study was that cardio-
vascular diseases are the most frequent cause of death in
patients with asthma. And compared with COPD pa-
tients, deaths due to exacerbations and malignancies
were less frequent. These findings are particularly rele-
vant given the limited information on this topic.
Our study was designed to include deaths of patients
with asthma of any age and both sexes; consequently it
Table 4 Multivariate analysis of factors associated with death due to cardiovascular diseases (crude and adjusted
rates)
n Odds ratio crude CI 95% (OR crude) Odds ratio adjusted CI 95% (OR adjusted)
Asthma - high certainty 26 0.69 0.26 - 1.82 0.64 0.23 - 1.77
Asthma - probable 56 1.49 0.85 - 2.62 1.1 0.60 - 2.01
COPD 283 0.775 0.58 - 1.04 0.84 0.60 - 1.18
Former smoker 764 0.88 0.73 - 1.07 0.96 0.74 - 1.24
Smoker 367 0.6 0.45 - 0.79 0.93 0.67 - 1.30
Age 2826 1.03 1.02 - 1.04 1.02 1.02 - 1.03
Sex 2816 0.707 0.60 - 0.84 0.83 0.66 - 1.03
Hyperlipidaemia 674 2.01 1.67 - 2.43 1.82 1.49 - 2.22
Diabetes 757 1.87 1.56 - 2.25 1.57 1.29 - 1.90
Footnote: 95% CI, 95% confidence interval OR, odds ratio.
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of asthmatics than previous studies carried out in spe-
cific sub-groups. For instance, de Marco et al19 evalu-
ated the causes of death of 47 asthmatics aged 20 to
44 years, and found that 34% died due to malignancies
and 17% of accidents. Similarly, Camargo et al [17] ana-
lyzed deaths of 87 women with asthma (all nurses) aged
30 to 55 years, of whom 31% of deaths were malignan-
cies and 22% cardiovascular diseases.
Another key results from our study comes from the
inclusion of deaths of COPD patients. Whereas in
asthma cardiovascular diseases constitute the most fre-
quent cause (29.3%), malignancies were the most fre-
quent cause (26.5%) in COPD, likely associated with a
higher cumulative tobacco exposure. Similarly, patients
with asthma died less frequently than patients with
COPD of respiratory failure or during exacerbation of
their disease (6.0% vs. 25.5%), due to lung cancer (1.2%
against 14.5%) and due to pneumonia (6% against
10.3%). The finding that patients with asthma, in contrastTable 5 Results of the multivariate analysis performed to
determine the possible association of the previous
diagnosis of asthma with causes of death from heart
failure
Odds ratio CI 95% P-value
Asthma 1.57 0.83-2.99 0.16
Diabetes 1.20 0.89-1.61 0.21
Former smoker 0.79 0.53-1.16 0.23
Smoker 0.55 0.30 - 1.02 0.05
Age 1.02 1.01 - 1.03 <0.001
Sex 0.79 0.57 - 1.11 0.18
Hyperlipidaemia 1.07 0.82 - 1.41 0.58
AHT 1.75 1.13 - 2.69 <0.001
Footnote:
CI 95%, confidence interval at 95%.
AHT, arterial hypertension.to COPD patients, die relatively infrequently from an ex-
acerbation of their disease, was well-documented in sev-
eral earlier series. Silverstein et al [16] found in a cohort of
2,499 persons with asthma that only 4% of the 140 deaths
recorded during 14 years of follow-up were by an episode
of exacerbation. This frequency is very similar (4.6%) out
from 87 deaths reported by Camargo et al [17]. Contrary
in COPD, serious worsening constitutes one of the most
frequent causes of death. In the TORCH study [12] this
was determined as the cause of 35% of deaths in 875 de-
ceased COPD patients. Similarly, lung cancer constitutes a
frequent cause of death in COPD: 21% in the TORCH
study [12], and 38% in the Lung Health Study [13]; as
above mentioned, it is not a frequent cause of death in
asthma. Finally in terms of differences in the frequency of
pneumonia as cause of death in these two diseases. It had
been suggested that patients with COPD treated with in-
haled corticosteroids have a greater risk of contracting
pneumonia, but do not die of it [12,30], and some authors
have suggested a potential beneficial effect, or at least not
a deleterious effect, of the outpatient use of inhaled cor-
ticosteroid in COPD or asthmatics patients who developed
pneumonia [31,32]. In our series, there is a considerable
percentage of patients with COPD who died of pneumonia,
but not higher than in the group of patients without previ-
ous lung pathology or asthmatics patients.
Paradoxically, since patients with asthma are nowadays
more likely to survive with close to normal longevity, it
resulted in an increase in prevalence of certain comor-
bidities associated with the disease having a significant
impact on their quality of life and probably also on their
specific causes of death [33]. Among others, the cardio-
vascular diseases are significant, and in particular, car-
diac disease and cerebrovascular accidents, especially in
the elderly, where their prevalence tends to be similar to
that of COPD [8,20]. Independently of the alleged role
by inhaled β2-adrenergic agonist in enhancing cardiac
comorbidities and death, both in COPD and asthma
Soto-Campos et al. BMC Pulmonary Medicine 2013, 13:73 Page 7 of 8
http://www.biomedcentral.com/1471-2466/13/73[34], an endothelial pathogeny linked to bronchial in-
flammation has been invoked as possibly responsible for
the cardiovascular diseases associated with or coincident
with asthma. Some studies have correlated bronchial in-
flammation with the production of C reactive protein
(CRP) in the vascular endothelium of the bronchial
tubes, through the stimulation of IL-6. CRP, in turn, has
been implicated directly in atherosclerosis and its com-
plications [35,36]. This would result in a lesion of the
vascular endothelium and, in consequence, the develop-
ment of cardiovascular disease. A similar mechanism
has also been suggested in the pathogeny of endothelial
lesions of COPD [37]. On the other hand, the possible
role of the cysteinyl leukotrienes has been proposed; in
addition to constituting one of the principal inflamma-
tory mediators of asthma, these molecules may cause
endothelial lesion or dysfunction [38]. Particularly in
women, in whom they are promoted by circulating es-
trogens, cysteinyl leukotrienes could contribute to the
greater incidence of cardiovascular diseases observed in
these patients. Hence those patients with active asth-
matic inflammatory disease, who therefore produce more
leukotrienes, would have a greater risk of suffering cardio-
vascular diseases [39,40]. The hypothesis is coherent with
previous observations particularly in asthmatic women, in
whom the association with suffering or dying from cardio-
vascular, and especially cerebrovascular diseases, appears
more consistent [17,26,27]. Our results, 78% of female
asthma deaths who presented an exceptionally aggressive
asthmatic disease support that hypothesis. Of these, 49%
were suffering a severe or moderate asthma, 85.5% were
not receiving sufficient monitoring of the disease and the
mean of previous hospital admissions for asthma was two.
All of them were largely modifiable factors. In addition,
they had a greater proportion of obese patients (32.8%) and
overall a significantly greater BMI (mean of 27.6 kg/cm2),
in comparison with the two reference groups as suggested
elsewhere [41], it could contribute to a greater risk of
accompanying vascular disease. However, the multivariate
study carried out did not confirm the association between
asthma and death from a cardiovascular disease (OR 0.95;
p = 0.9809), nor with any of its variants considered in the
study. Perhaps a greater sample size could have identified
a statistical association, for example, with death due to
heart failure which showed results close to significance, in
agreement with Proser et al [42], reporting a strong asso-
ciation of both (OR 4.62).
Although the study is subject to the customary meth-
odological limitations due to the retrospective collection
of information from patients clinical records, we consider
that, with our choice of study design with two reference
populations this potential limitation was lessened. Data
quality on causes of death is greater when obtained from
hospital charts in comparison when obtained via deathcertificates of deaths occurring outside the hospital con-
text, in which the nature of the cause of death can often
be questionable. Perhaps one strength here is the rigor
employed in the assumption of the diagnosis of asthma in
all deaths analyzed. Anyway, our conclusions must be
tempered by the large number of statistical tests carried
out.
To conclude, the most common causes of death of
asthmatics in our study were those related to cardiovas-
cular diseases and, unlike COPD patients, there were
significantly fewer deaths due to exacerbation and lung
cancer. These findings are relevant, as mortality in
asthma has been analyzed only partially and mostly
within subgroups. We did not observed an association
between suffering asthma and death from a cardiovascu-
lar disease, but similar studies need to be conducted
with larger samples of asthmatics, in which causes of
death should be analyzed rigorously. Until such informa-
tion be available, the present study could provide argu-
ments for adopting a more proactive attitude in routine
clinical practice, towards the prevention and treatment
of cardiovascular diseases in patients with asthma, par-
ticularly in those of advanced age.
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